BOSTON--(BUSINESS WIRE)--BioPharm Insight, the most comprehensive life science market intelligence and analytics solution, recently released an exclusive report on Immuno-Oncology. The report features in depth coverage of Anti PD-1/PD-L1, CAR-Ts and Vaccines.
While drugs like Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda have thrown the limelight once again on Immuno-Oncology, read BioPharm Insight’s report to find out what key opinion leaders have to say about their true market potential given associated toxicities.
